2015
DOI: 10.1038/eye.2015.142
|View full text |Cite
|
Sign up to set email alerts
|

Month-6 primary outcomes of the READ-3 study (Ranibizumab for Edema of the mAcula in Diabetes—Protocol 3 with high dose)

Abstract: Purpose To compare 2.0 mg ranibizumab (RBZ) injections with 0.5 mg RBZ for eyes with center-involved diabetic macular edema (DME) and a central subfield thickness (CFT) of ≥ 250 μm on time-domain optical coherence tomography. Design Randomized, controlled, multicenter clinical trial. Methods Eligible eyes were randomized in a 1:1 ratio to 0.5 mg (n = 77) or 2.0 mg (n = 75) RBZ. Study eyes received 6-monthly injections. Main outcome measures The primary outcome measure was the mean change in best corrected visu… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
26
0

Year Published

2016
2016
2022
2022

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 37 publications
(26 citation statements)
references
References 7 publications
0
26
0
Order By: Relevance
“…It is not necessary to inject 0.08 mL instead of 0.05 mL to achieve the standard dose of 2 mg, as this extra volume can result in increase in intraocular pressure and jeopardise the already fragile retinal circulation. The best argument comes from the VIEW trials, where 0.5 and 2.0 mg produced quite comparable outcomes,6 7 similar to the READ-3 trial that showed no advantage to quadruple the dose of intravitreal ranibizumab 17…”
Section: Discussionmentioning
confidence: 99%
“…It is not necessary to inject 0.08 mL instead of 0.05 mL to achieve the standard dose of 2 mg, as this extra volume can result in increase in intraocular pressure and jeopardise the already fragile retinal circulation. The best argument comes from the VIEW trials, where 0.5 and 2.0 mg produced quite comparable outcomes,6 7 similar to the READ-3 trial that showed no advantage to quadruple the dose of intravitreal ranibizumab 17…”
Section: Discussionmentioning
confidence: 99%
“…In the more recent READ-3 trial (RBZ for edema of the mAcula in Diabetes-Protocol 3 with high dose), intravitreal RBZ was tested at different dosages: 2.0 versus 0.5 mg [22] . At month-6 (primary outcome), after 6 monthly injections in both groups, there was no statistically significant difference in the 2 arms in terms of the number of letters gained.…”
Section: © 2017 S Karger Ag Baselmentioning
confidence: 99%
“…Of the remainder, who were switched to a 2.0 mg dose, 50% demonstrated anatomical improvement. The Ranibizumab for Edema of the Macula in Diabetes: Protocol 3 With High Dose (READ-3) study (ClinicalTrials.gov: NCT01077401) randomised participants with DMO to receive either 0.5 mg or 2.0 mg of ranibizumab; 6 month results showed no benefit with the higher dose of therapy [102]. It is likely that the effects of higher doses of ranibizumab may be equivocal.…”
Section: Anti-vegf Therapymentioning
confidence: 99%